Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

19 questions · 19 findings · 5 reviews

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 0 · 0%Low 2 · 10.5%Moderate 8 · 42.1%High 9 · 47.4%

Chemotherapy vs placebo, best supportive care (BSC) or no treatment

Overall survival · advanced gastric and oesophago‐gastric junction adenocarcinoma

Chemotherapy probably leads to lower overall survival compared with placebo, best supportive care (BSC) or no treatment (moderate certainty).

1 finding from 1 review

Chemotherapy vs chemotherapy alone

Overall survival (taxane‐containing doublet therapy vs taxane monotherapy) · advanced gastric adenocarcinoma

Chemotherapy showed no clear difference in overall survival (taxane‐containing doublet therapy vs taxane… compared with chemotherapy (low certainty).

1 finding from 1 review

Perioperative chemotherapy vs primary surgery

Overall survival among all patients · resectable adenocarcinoma of the stomach, gastroesophageal junction, and lower esophagus

Perioperative chemotherapy leads to lower overall survival among all patients compared with primary surgery (high certainty).

1 finding from 1 review

Perioperative chemotherapy vs primary surgery

Overall survival by tumor site ‐ Stomach · resectable adenocarcinoma of the stomach, gastroesophageal junction, and lower esophagus

Perioperative chemotherapy showed no clear difference in overall survival by tumor site ‐ Stomach compared with primary surgery (high certainty).

1 finding from 1 review

Perioperative chemotherapy vs primary surgery

Overall survival by tumor site ‐ Esophagus · resectable adenocarcinoma of the stomach, gastroesophageal junction, and lower esophagus

Perioperative chemotherapy showed no clear difference in overall survival by tumor site ‐ Esophagus compared with primary surgery (high certainty).

1 finding from 1 review

Perioperative chemotherapy vs primary surgery

Overall survival by tumor site ‐ GE junction · resectable adenocarcinoma of the stomach, gastroesophageal junction, and lower esophagus

Perioperative chemotherapy leads to lower overall survival by tumor site ‐ GE junction compared with primary surgery (high certainty).

1 finding from 1 review

Perioperative chemotherapy vs primary surgery

Overall survival by type of data ‐ Aggregated data · resectable adenocarcinoma of the stomach, gastroesophageal junction, and lower esophagus

Perioperative chemotherapy probably leads to lower overall survival by type of data ‐ Aggregated data compared with primary surgery (moderate certainty).

1 finding from 1 review

Perioperative chemotherapy vs primary surgery

Overall survival by type of data ‐ Individual patient data · resectable adenocarcinoma of the stomach, gastroesophageal junction, and lower esophagus

Perioperative chemotherapy leads to lower overall survival by type of data ‐ Individual patient data compared with primary surgery (high certainty).

1 finding from 1 review

Perioperative chemotherapy vs primary surgery

Overall survival by chemo‐/radiotherapy ‐ Chemotherapy only · resectable adenocarcinoma of the stomach, gastroesophageal junction, and lower esophagus

Perioperative chemotherapy leads to lower overall survival by chemo‐/radiotherapy ‐ Chemotherapy only compared with primary surgery (high certainty).

1 finding from 1 review

Perioperative chemotherapy vs primary surgery

Overall survival by chemo‐/radiotherapy ‐ Chemoradiotherapy · resectable adenocarcinoma of the stomach, gastroesophageal junction, and lower esophagus

Perioperative chemotherapy probably leads to lower overall survival by chemo‐/radiotherapy ‐ Chemoradiotherapy compared with primary surgery (moderate certainty).

1 finding from 1 review

Summary of findings table (subcomparison 3): chemotherapy agent(s) plus control intervention vs control intervention

Overall survival · palliative participants with esophageal and GE‐junction carcinoma

Summary of findings table (subcomparison 3): chemotherapy agent(s)… probably leads to lower overall survival compared with control intervention alone (moderate certainty).

1 finding from 1 review

Summary of findings table (subcomparison 5): chemotherapy or targeted therapy agent(s) plus control intervention vs control intervention

Overall survival · palliative participants with esophageal and GE‐junction carcinoma

Summary of findings table: chemotherapy or targeted therapy agent(s)… leads to lower overall survival compared with control intervention alone (high certainty).

1 finding from 1 review

Summary of findings table (subcomparison 1): chemotherapy or targeted therapy plus best supportive care (BSC) vs BSC

Overall survival · palliative participants with esophageal and GE‐junction carcinoma

Summary of findings table (subcomparison 1): chemotherapy or… leads to lower overall survival compared with BSC (high certainty).

1 finding from 1 review

Summary of findings table (subcomparison 2): second‐line chemotherapy or targeted therapy agent(s) plus control intervention vs control intervention

Overall survival · palliative participants with esophageal and GE‐junction carcinoma previously treated with chemotherapy

Summary of findings table (subcomparison 2): second‐line… probably leads to lower overall survival compared with control intervention alone (moderate certainty).

1 finding from 1 review

ATRA in addition to chemotherapy vs chemotherapy alone

Mortality (calculated instead of overall survival) · adults with acute myeloid leukaemia (AML) (non‐acute promyelocytic leukaemia (APL))

ATRA in addition to chemotherapy showed no clear difference in mortality (instead of overall survival) compared with chemotherapy only (moderate certainty).

1 finding from 1 review